Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Oxford-Emergent Tuberculosis Consortium (OETC), a joint venture of Emergent BioSolutions and the University of Oxford (Oxford), has vaccinated the last of the 2,784 infants in a Phase IIb trial evaluating tuberculosis (TB) vaccine, MVA85A.
Subscribe to our email newsletter
The Phase IIb trial was originally started in July 2009 and involves a two-year follow up on the infants vaccinated as part of the trial to investigate whether the vaccine candidate has conferred protection against TB.
Emergent president and chief operating officer Daniel Abdun-Nabi said the company has joined the fight against TB when it formed OETC with Oxford to further develop MVA85A.
"We are pleased to complete the vaccination of our targeted 2,784 infants, which is the largest number of infants enrolled in any TB vaccine clinical trial," Abdun-Nabi said.
The clinical trial in Worcester, South Africa, is being conducted by the University of Cape Town’s South African Tuberculosis Vaccine Initiative (SATVI), in partnership with Aeras, the clinical sponsor of the study, and the Wellcome Trust.